var data={"title":"Iobenguane: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iobenguane: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/370650?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iobenguane-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iobenguane: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6860203\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AdreView&trade;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815128\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815282\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Thyroid protective agents (SSKI, Lugol's solution or potassium iodide), should be given at least 1 hour prior to administration (in patients at risk for accumulation in thyroid). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radioimaging:</b> IV: 10 mCi (370 MBq) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Heart failure:</i> Adults: Begin anterior planar chest imaging 4 hours (&plusmn; 10 minutes) following administration; single photon emission computed tomography (SPECT) may then be performed. Low-energy high-resolution is the recommended imaging collimator; the recommended matrix for planar images is 128x128; position camera to include entire heart and as much of upper chest as possible within field. Follow details within manufacturer&rsquo;s labeling to determine heart to mediastinum (H/M) ratio.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pheochromocytoma and neuroblastoma:</i> Perform whole body planar scintigraphy imaging 18-30 hours after iobenguane I 123 administration; SPECT may be performed following planar scintigraphy (as appropriate).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815323\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Thyroid protective agents (SSKI, Lugol's solution or potassium iodide), should be given at least 1 hour prior to administration (in patients at risk for accumulation in thyroid). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radioimaging:</b> <i>Pheochromocytoma and neuroblastoma:</i> Perform whole body planar scintigraphy imaging 18-30 hours after iobenguane I 123 administration; single photon emission computed tomography (SPECT) may be performed following planar scintigraphy (as appropriate). IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 month to 16 years and &lt;70 kg: Dose according to body weight; see table.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;16 years and &ge;70 kg: 10 mCi (370 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;16 years: Refer to adult dosing</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Iobenguane I 123 Pediatric Dosing by Body Weight: (Children 1 Month to 16 Years and &lt;70 kg)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Weight (kg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">mCi Dose</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">MBq Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">37</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">52</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">85.1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.7</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">99.9</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">118.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">133.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">148</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">162.8</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">170.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">22</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">185</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">24</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">196.1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">26</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">207.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">28</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">214.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">229.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">32</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">240.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">251.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">262.7</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">38</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">270.1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">281.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">42</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">288.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">296</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">46</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">303.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">48</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">314.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">325.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">52-54</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">333</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">56-58</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">340.4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60-62</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">355.2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">64-66</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">362.6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">68</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.9</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">366.3</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815343\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962253\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, radiation exposure may be increased in patients with severe renal impairment, use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962254\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\"> No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815353\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AdreView&trade;: Iobenguane sulfate 0.08 mg and I 123 74 MBq (2 mCi) per mL (5 mL) [contains benzyl alcohol] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815126\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815349\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer intravenously over 1-2 minutes. May flush with NS to ensure full delivery of dose. Prior to administration, a thyroid-protective agent should be started (in patients at risk for accumulation in thyroid). Ensure adequate hydration before and after treatment; instruct patient to void frequently for 48 hours after administration to minimize bladder exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815131\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">As an adjunct to other diagnostic tests, in the detection of primary or metastatic pheochromocytoma or neuroblastoma; scintigraphic assessment of sympathetic myocardium innervation (by measurement of heart to mediastinum [H/M] ratio of radioactivity uptake) in patients with New York Heart Association class II or class III heart failure and LVEF &le;35% (may help identify lower 1 and 2 year mortality risks, indicated by H/M ratio &ge;1.6) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15245845\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815141\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Local: Injection site reaction (hematoma/bruising: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bleeding at injection site, dizziness, flushing, headache, hypersensitivity (rare), hypertension (transient), pruritus, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815137\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iobenguane, iobenguane sulfate, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815138\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions have been reported. Use with extreme caution in patients with iodine or iodine-contrast agent hypersensitivity (base treatment decision on assessment of benefit versus risk). Appropriate equipment and emergency medications should be available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use has not been evaluated for selecting therapeutic intervention or monitoring treatment response; the H/M ratio has not been used in identifying patients with a higher mortality risk. Patients were excluded from clinical studies if the risks of withdrawing interacting cardiovascular medications outweighed the potential value of imaging.      </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May cause a transient increase in blood pressure (although not observed in clinical trials). Monitor blood pressure prior to administration and intermittently for 30 minutes following administration. Appropriate emergency cardiac and antihypertensive treatments should be available during use. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; safety and efficacy have not been established. Patients with severe renal impairment may have delayed elimination, therefore, increasing the radiation dose and decreasing quality of images. Not dialyzable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sympathetic nervous system disorders: Patients with sympathetic nervous system disorders (eg, Parkinson&rsquo;s disease or multiple system atrophy) may have reduced cardiac uptake of iobenguane; may result in imaging errors (eg, false negatives).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Consider withdrawing antihypertensives which deplete norepinephrine stores or inhibit reuptake, antidepressants which inhibit norepinephrine transporter function, and sympathomimetic amines. Medications which interfere with norepinephrine uptake in neuroendocrine tumors may lead to false negative imaging; may also interfere with imaging in patients with heart failure. The amount of time necessary for interruption prior to administration of iobenguane I 123 has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved  by the applicable regulatory authority.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Administer thyroid blocking medications (eg, potassium iodide oral solution, potassium perchlorate) at least 1 hour prior to administration (in patients at risk for accumulation in thyroid); long-term risk for thyroid neoplasia can occur from failure to block thyroid uptake of iodine 123. Thyroid blockade is not necessary for thyroidectomy patients and may not be necessary in patients with a short life-expectancy. Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 48 hours following administration to decrease radiation exposure. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299525\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6833886\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9084&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May diminish the therapeutic effect of Iobenguane I 123.<b> Exceptions: </b>Apraclonidine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the therapeutic effect of Iobenguane I 123.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815132\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815133\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed. The effect on future fertility is unknown. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815136\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if iobenguane I 123 is excreted in breast milk. Iodine 123 is excreted into human milk, therefore, due to potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended. May consider interrupting breast-feeding for 6 days after administration of iobenguane I 123 to minimize risk to infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815348\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dietary sources of iodine include cow's milk and dairy products, fish, seaweed, eggs, chocolate, and iodized salt. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815352\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">TSH, prior to therapy and every six months for life (Hamnvik, 2011). Pulse and blood pressure prior to administration and intermittently for 30 minutes following; monitor for hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815147\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Iobenguane is structurally similar to norepinephrine and therefore is taken up and stored in adrenergic tissue such as adrenal medulla, heart, liver, lungs, salivary glands, and spleen. Iobenguane is bound to radioactive iodine in order to obtain organ and tissue images.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6815149\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Increased in adrenergically innervated tissues (eg, heart, salivary glands, adrenal medulla)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Has not been characterized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Iodine 123: 13.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (70 % to 90%) within 4 days (normal renal function); feces &lt;1%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321886\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (AdreView Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mci/5 mL (5 mL): $4,723.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Currie GM, Iqbal B, Wheat JM, et al, &ldquo;Risk Stratification in Heart Failure Using <sup>123</sup>I-MIBG,&rdquo; <i>J Nucl Med Technol</i>, 2011, 39(4):295-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/21969356/pubmed\" target=\"_blank\" id=\"21969356\">21969356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson AF, Deng H, Lombard J, et al, &ldquo;123I-Meta-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis,&rdquo; <i>J Clin Endocrinol Metab</i>, 2010, 95(6):2596-606. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iobenguane-drug-information/abstract-text/20392867/pubmed\" target=\"_blank\" id=\"20392867\">20392867</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9084 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6860203\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6815128\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6815282\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6815323\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6815343\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962253\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962254\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6815353\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6815126\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6815349\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6815131\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15245845\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6815141\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6815137\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6815138\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299525\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6833886\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6815132\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6815133\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6815136\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6815348\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6815352\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6815147\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6815149\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321886\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9084|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iobenguane-patient-drug-information\" class=\"drug drug_patient\">Iobenguane: Patient drug information</a></li></ul></div></div>","javascript":null}